NCT05163249View on ClinicalTrials.gov

Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

May 31, 2022

Primary Completion Date

April 30, 2024

Study Completion Date

August 31, 2026

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Osimertinib

osimertinib, 80mg, daily, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met

DRUG

Savolitinib

savolitinib 300mg BID, P.O. Until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met

Trial Locations (1)

510080

Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou

All Listed Sponsors
lead

Guangdong Association of Clinical Trials

OTHER

NCT05163249 - Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC | Biotech Hunter | Biotech Hunter